HIV-1 reverse transcriptase complex with DNA and nevirapine reveals nonnucleoside inhibition mechanism

Combinations of nucleoside and non-nucleoside inhibitors (NNRTIs) of HIV-1 reverse transcriptase (RT) are widely used in anti-AIDS therapies. Five NNRTIs, including nevirapine, are clinical drugs; however, the molecular mechanism of inhibition by NNRTIs is not clear. We determined the crystal structures of RT–DNA–nevirapine, RT–DNA, and RT–DNA–AZT-triphosphate complexes at 2.85-, 2.70- and 2.80-Å resolution, respectively. The RT–DNA complex in the crystal could bind nevirapine or AZT-triphosphate but not both. Binding of nevirapine led to opening of the NNRTI-binding pocket. The pocket formation caused shifting of the 3′ end of the DNA primer by ~5.5 Å away from its polymerase active site position. Nucleic acid interactions with fingers and palm subdomains were reduced, the dNTP-binding pocket was distorted and the thumb opened up. The structures elucidate complementary roles of nucleoside and non-nucleoside inhibitors in inhibiting RT.

[1]  Elio A. Abbondanzieri,et al.  Slide into Action: Dynamic Shuttling of HIV Reverse Transcriptase on Nucleic Acid Substrates , 2008, Science.

[2]  S. Sarafianos,et al.  Nonnucleoside reverse transcriptase inhibitors are chemical enhancers of dimerization of the HIV type 1 reverse transcriptase , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[3]  H. M. Vinkers,et al.  Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. , 2004, Journal of medicinal chemistry.

[4]  D. Cooper,et al.  A controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenaemic HIV‐infected patients , 1996, AIDS.

[5]  Roger A. Jones,et al.  Synthesis of Guanosine and Deoxyguanosine Phosphoramidites with Cross-Linkable Thioalkyl Tethers for Direct Incorporation into RNA and DNA , 2009, Nucleosides, nucleotides & nucleic acids.

[6]  T. Hahn.  International tables for crystallography , 2002 .

[7]  Christopher M. Bailey,et al.  Defining a Molecular Mechanism of Synergy between Nucleoside and Nonnucleoside AIDS Drugs* , 2004, Journal of Biological Chemistry.

[8]  S. Doublié,et al.  Caught bending the A-rule: crystal structures of translesion DNA synthesis with a non-natural nucleotide. , 2007, Biochemistry.

[9]  A. Lazzarin,et al.  Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial , 2011, The Lancet.

[10]  Eddy Arnold,et al.  Crystallography of biological macromolecules , 2001 .

[11]  Kevin Cowtan,et al.  research papers Acta Crystallographica Section D Biological , 2005 .

[12]  A. Skalka,et al.  The retroviral enzymes. , 1994, Annual review of biochemistry.

[13]  J. Torella,et al.  Conformational transitions in DNA polymerase I revealed by single-molecule FRET , 2009, Proceedings of the National Academy of Sciences.

[14]  T. Steitz,et al.  Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. , 1992, Science.

[15]  Roger A. Jones,et al.  Structural basis of HIV-1 resistance to AZT by excision , 2010, Nature Structural &Molecular Biology.

[16]  B. Canard,et al.  The Y181C Substitution in 3′-Azido-3′-deoxythymidine-resistant Human Immunodeficiency Virus, Type 1, Reverse Transcriptase Suppresses the ATP-mediated Repair of the 3′-Azido-3′-deoxythymidine 5′-Monophosphate-terminated Primer* , 2003, Journal of Biological Chemistry.

[17]  M. Wainberg,et al.  Effects of Non-nucleoside Inhibitors of Human Immunodeficiency Virus Type 1 in Cell-free Recombinant Reverse Transcriptase Assays (*) , 1995, The Journal of Biological Chemistry.

[18]  Martin Phillips,et al.  Toward the structural genomics of complexes: crystal structure of a PE/PPE protein complex from Mycobacterium tuberculosis. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[19]  D W Rodgers,et al.  The structure of unliganded reverse transcriptase from the human immunodeficiency virus type 1. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[20]  Gabriel Waksman,et al.  Crystal structures of open and closed forms of binary and ternary complexes of the large fragment of Thermus aquaticus DNA polymerase I: structural basis for nucleotide incorporation , 1998, The EMBO journal.

[21]  W. Denny,et al.  CRYSTALLOGRAPHY OF BIOLOGICAL MACROMOLECULES , 2005 .

[22]  Stephen H. Hughes,et al.  Nonnucleoside Inhibitor Binding Affects the Interactions of the Fingers Subdomain of Human Immunodeficiency Virus Type 1 Reverse Transcriptase with DNA , 2004, Journal of Virology.

[23]  R. Goody,et al.  Human immunodeficiency virus reverse transcriptase substrate-induced conformational changes and the mechanism of inhibition by nonnucleoside inhibitors. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[24]  S. Benkovic,et al.  DNA polymerase fidelity: kinetics, structure, and checkpoints , 2004 .

[25]  Yvonne Jones,et al.  High resolution structures of HIV-1 RT from four RT–inhibitor complexes , 1995, Nature Structural Biology.

[26]  A. D. Clark,et al.  Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[27]  N. Sluis-Cremer,et al.  Probing nonnucleoside inhibitor‐induced active‐site distortion in HIV‐1 reverse transcriptase by transient kinetic analyses , 2007, Protein science : a publication of the Protein Society.

[28]  M. Parniak,et al.  Phenotypic mechanism of HIV-1 resistance to 3'-azido-3'-deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase. , 1998, Biochemistry.

[29]  Randy J. Read,et al.  Acta Crystallographica Section D Biological , 2003 .

[30]  Roger A. Jones,et al.  Structures of HIV-1 RT–DNA complexes before and after incorporation of the anti-AIDS drug tenofovir , 2004, Nature Structural &Molecular Biology.

[31]  Ivet Bahar,et al.  Conformational changes in HIV-1 reverse transcriptase induced by nonnucleoside reverse transcriptase inhibitor binding. , 2004, Current HIV research.

[32]  A. D. Clark,et al.  Trapping HIV-1 Reverse Transcriptase Before and After Translocation on DNA* , 2003, The Journal of Biological Chemistry.

[33]  M. Wainberg,et al.  Compensation by the E138K Mutation in HIV-1 Reverse Transcriptase for Deficits in Viral Replication Capacity and Enzyme Processivity Associated with the M184I/V Mutations , 2011, Journal of Virology.

[34]  T. Steitz,et al.  Structure of DNA polymerase I Klenow fragment bound to duplex DNA , 1993, Science.

[35]  Roger A. Jones,et al.  Structural Basis for the Role of the K65R Mutation in HIV-1 Reverse Transcriptase Polymerization, Excision Antagonism, and Tenofovir Resistance* , 2009, The Journal of Biological Chemistry.

[36]  S. Benkovic,et al.  Rate-limiting steps in the DNA polymerase I reaction pathway. , 1985, Biochemistry.

[37]  Joseph D. Bauman,et al.  Crystal engineering of HIV-1 reverse transcriptase for structure-based drug design , 2008, Nucleic acids research.

[38]  M. Wainberg,et al.  Compensation by the E 138 K Mutation in HIV-1 Reverse Transcriptase for Deficits in Viral Replication Capacity and Enzyme Processivity Associated with the M 184 I / V Mutations , 2011 .

[39]  A. D. Clark,et al.  Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant. , 1996, Journal of molecular biology.

[40]  D. Stammers,et al.  Structural basis for drug resistance mechanisms for non-nucleoside inhibitors of HIV reverse transcriptase. , 2008, Virus research.

[41]  D W Barry,et al.  3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[42]  K. White,et al.  Visualizing the molecular interactions of a nucleotide analog, GS-9148, with HIV-1 reverse transcriptase-DNA complex. , 2010, Journal of molecular biology.

[43]  J. DeStefano,et al.  Characterization of an RNase H deficient mutant of human immunodeficiency virus-1 reverse transcriptase having an aspartate to asparagine change at position 498. , 1994, Biochimica et biophysica acta.

[44]  T. Steitz.  DNA Polymerases: Structural Diversity and Common Mechanisms* , 1999, The Journal of Biological Chemistry.

[45]  S. Sarafianos,et al.  Touching the heart of HIV-1 drug resistance: the fingers close down on the dNTP at the polymerase active site. , 1999, Chemistry & biology.

[46]  K A Johnson,et al.  Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors , 1995, Science.

[47]  C. Cruchaga,et al.  Non-nucleoside Inhibitors of HIV-1 Reverse Transcriptase Inhibit Phosphorolysis and Resensitize the 3′-Azido-3′-deoxythymidine (AZT)-resistant Polymerase to AZT-5′-triphosphate* , 2003, Journal of Biological Chemistry.

[48]  K. Diederichs,et al.  Replication through an abasic DNA lesion: structural basis for adenine selectivity , 2010, The EMBO journal.

[49]  Jayanta Mukhopadhyay,et al.  The RNA Polymerase “Switch Region” Is a Target for Inhibitors , 2008, Cell.

[50]  R. Eritja,et al.  Kinetics of deoxyribonucleotide insertion and extension at abasic template lesions in different sequence contexts using HIV-1 reverse transcriptase. , 1993, The Journal of biological chemistry.

[51]  U Helena Danielson,et al.  Biosensor-based kinetic characterization of the interaction between HIV-1 reverse transcriptase and non-nucleoside inhibitors. , 2006, Journal of medicinal chemistry.

[52]  G L Verdine,et al.  Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. , 1998, Science.

[53]  A. D. Clark,et al.  Structure of unliganded HIV-1 reverse transcriptase at 2.7 A resolution: implications of conformational changes for polymerization and inhibition mechanisms. , 1996, Structure.

[54]  A. D. Clark,et al.  Crystal structure of HIV‐1 reverse transcriptase in complex with a polypurine tract RNA:DNA , 2001, The EMBO journal.

[55]  Meitian Wang,et al.  Crystal Structures of the RNA-dependent RNA Polymerase Genotype 2a of Hepatitis C Virus Reveal Two Conformations and Suggest Mechanisms of Inhibition by Non-nucleoside Inhibitors* , 2005, Journal of Biological Chemistry.

[56]  A. Mian,et al.  A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase. , 1999, Molecular cell.

[57]  Elio A. Abbondanzieri,et al.  Dynamic binding orientations direct activity of HIV reverse transcriptase , 2008, Nature.